Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Annals of the New York Academy of Sciences|October 20, 2010
NF-κB and innate immunity in ischemic strokeOlivier A Harari, James K Liao
Patient Preference and Adherence|March 23, 2026
A Qualitive Investigation of Geographic Disparities in Genetic Testing and Care Access for Amyotrophic Lateral Sclerosis: Insights From Patient Journey MappingNadia Sethi, Oren A Levy, Angela Richardson, et al.
Circulation Research|April 1, 2006
Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathwayOlivier A Harari, Pilar Alcaide, Daniela Ahl, et al.
European Heart Journal|June 9, 2009
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery diseaseAlejandro Recio-Mayoral, Justin C Mason, Juan C Kaski, et al.
British Journal of Clinical Pharmacology|November 19, 2016
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisSophie Glatt, Eric Helmer, Birgit Haier, et al.
The Journal of Biological Chemistry|September 6, 2007
A protein kinase Cepsilon-anti-apoptotic kinase signaling complex protects human vascular endothelial cells against apoptosis through induction of Bcl-2Rivka Steinberg, Olivier A Harari, Elaine A Lidington, et al.
Orphanet Journal of Rare Diseases|August 8, 2024
Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessmentsLeighann Litcher-Kelly, Ahmet Ozen, Sarah Ollis, et al.
Orphanet Journal of Rare Diseases|February 11, 2025
The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare conditionLeighann Litcher-Kelly, Ahmet Ozen, Sarah Ollis, et al.
Lancet (London, England)|January 26, 2024
Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 studyAhmet Ozen, Voranush Chongsrisawat, Asena Pinar Sefer, et al.
JCI Insight|June 23, 2025
A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humansHeinrich E Lob, Nikhil Singh, Kusha Mohammadi, et al.
Pageof 1